Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Furamidine (DB75) is a synthetic diamidine compound with potent antiparasitic activity, primarily known as the active metabolite of the oral prodrug pafuramidine (DB289)[1][2][3][4][5]. Furamidine exerts its trypanocidal effect by binding to the minor groove of DNA, thereby interfering with essential genetic processes in protozoal organisms[5]. It has demonstrated broad-spectrum activity against African trypanosomes, Pneumocystis jirovecii, Plasmodium spp. (malaria), and certain fungal pathogens[1][2][3][5]. The drug disrupts mitochondrial function in susceptible cells; yeast cells reliant on mitochondrial metabolism show particular sensitivity[3]. Furamidine is considered experimental and is not currently approved as a marketed pharmaceutical[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on furamidine.